Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 multiple ascending dose study of ALXN1830 in warm autoimmune hemolytic anemia
2021-001211-90Phase 2Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in warm autoimmune hemolytic anemia (wAIHA) and autoimmune haemolytic anaemia (AIHA) comparing ALXN1830 (orilanolimab) arm with Placebo arm (2 arms). Primary endpoint: Primary hemoglobin response without treatment escalation or transfusion. Started Jul 2021; status: terminated.
02
Drugs
orilanolimab
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)autoimmune haemolytic anaemia (AIHA)
Beyond the preview
Go deeper on 2021-001211-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001211-90.